Medicines: get scientific advice from the MHRA

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) provides a structured pathway for developers to obtain scientific advice throughout a medicine’s development and lifecycle. This guidance does not pertain to a specific company or individual inspection but outlines the standards for all pharmaceutical organizations operating under the UK regulatory framework, including the Human Medicines (Amendment etc.) (EU Exit) Regulations 2020. Developers can request written advice or meetings, including joint sessions with the National Institute for Health and Care Excellence (NICE), to align regulatory and clinical assessments. Key requirements for applicants include submitting a formal advice request form accompanied by a comprehensive list of questions and a briefing document. These materials, along with any required fees, must be submitted at least 15 working days before a scheduled meeting. Failure to meet these deadlines results in meeting delays. Post-meeting, the company must provide meeting notes within 15 working days. The MHRA typically issues a final advice letter within 30 working days of the meeting, except for broader scope consultations. It is important to note that this advice is non-binding and focuses on scientific issues such as clinical trial design, manufacturing processes, and pharmacovigilance plans. While UK-based small and medium-sized enterprises (SMEs) may qualify for fee waivers, most applicants must ensure timely payment to maintain their scheduled consultation.